Novartis oncology vet Stefan Scherer joins biotech migration to head clinical work, CAR-T partnership at Cellectis

Cellectis $CLLS has been busy since Allogene Therapeutics launched in April with a Pfizer deal that made them overnight partners, raising $164 million to hustle its off-the-shelf CAR-T therapies along the clinic. And it’s now hired a Novartis veteran to bolster that accelerated timeline.

Stefan Scherer

Stefan Scherer’s official title will be senior vice president clinical development and deputy chief medical officer, reporting to CMO and R&D chief Stéphane Depil from the French biotech’s New York office.

This will be Scherer’s second time around the C-suite as he joins the migration of Big Pharma research leaders into biotech. Before joining Novartis — eventually moving up to head of early development, strategy and innovation for US oncology — he had a stint as CMO at Swiss diagnostics company Biocartis. He worked on cancer biomarkers for Roche prior to that.

The team at Allogene led by Arie Belldegrun and David Chang — the top execs at Kite Pharma until Gilead bought them out for $12 billion — has taken charge of developing UCART19, Cellectis’ early-stage lead therapy.

Cellectis CEO André Choulika previously told Endpoints News he thinks that the collaboration between that team and his company’s know-how on gene editing will give them a shot at commercialization work in late 2021 or ’22. In a press release, he indicated that Scherer will likely play a key role in that partnership:

Stefan’s deep medical expertise, strong track record of alliance- and relationship-building and previous C-level experience, all position him to make an immediate impact on the development and long-term strategic planning for Cellectis’ innovative product portfolio.

Cellectis is also developing UCART123, which got back on track with a Phase I trial after getting hit by a clinical halt months ago.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,300+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Associate Principal, Life Sciences Partnerships
Flatiron Health New York City or San Francisco
Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC

Visit Endpoints Careers ->